← Russell 3000 cross-section

ZTS Zoetis Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$31.1bn
Revenue TTM
$9.5bn
Net income TTM
$2.6bn
Free cash flow
$2.4bn
Composite score
Sector rank
#328

Valuation

P / E
11.9
EV / EBITDA
EV / sales
4.0
FCF yield
7.60%
Earnings yield vs 10-yr
3.67pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
27.5%
EBITDA margin
ROE
83.1%
ROIC
Revenue growth
1.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For the six months ended June 30, 2026, approximately 46% of our revenue was denominated in foreign currencies. For the six months ended June 30, 2026, approximately 54% of our total revenue was in U.S. dollars. Our year-over-year total revenue growth was favorably impacted by approximately 2% from changes in foreign currency values relative to the U.S. dollar. GAAP reported net income attributable to Zoetis and reported EPS. …Zoetis Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →